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Background 
 Caused by Gram-negative, rod-shaped, toxigenic Vibrio 
cholerae O1 (>99% of global cases) or O139 
 Watery diarrhea that may be severe and rapidly fatal 
without proper treatment 
 Endemic in >50 countries; may also cause epidemics 
 Estimated 3–5 million cases of illness and 100,000–130,000 
deaths annually 
Countries reporting cholera deaths and imported 
cases to the World Health Organization, 2014 
World Health Organization Weekly epidemiological record. 2 Oct 2015. No. 40, 2015, 90, 517–544. 
http://www.who.int/wer/2015/wer9040.pdf?ua=1 
Countries reporting cholera deaths and imported 
cases to the World Health Organization, 2014 
World Health Organization Weekly epidemiological record. 2 Oct 2015. No. 40, 2015, 90, 517–544. 
http://www.who.int/wer/2015/wer9040.pdf?ua=1 
 Deaths reported by 24 countries in 
• Africa (1,882) 
• Asia (42) 
• Caribbean [Hispaniola] (307) 





















United Kingdom (14) 
United States (7) 
 
Microbiology 
 V. cholerae classified by O-antigen structure 
 >200 O serogroups have been identified 
 World Health Organization defines cholera as illness caused 
by toxigenic O1 and O139 (because they have caused cholera 
epidemics) 
• O1 biotypes: El Tor and classical 
• O1 serotypes: Inaba and Ogawa 
Pathogenesis 
 V. cholerae colonizes small intestine and produces cholera 
toxin 
 Cholera toxin  
• The A subunit causes secretory diarrhea 
• Five identical B subunits surround A subunit and bind toxin to cell 
membrane receptors 
Transmission 
 Easily transmitted by water and food contaminated by 
human feces or environmental reservoirs 
• Grows rapidly in warm, moist, non-acidic foods  
• Does not tolerate drying, acidity, or sunlight 
• Attaches to copepods (zooplankton), which can be consumed 
with contaminated water or food 
 Incubation period: hours to 5 days 
 Duration: 1 to a few days 
 Secondary cases rare if sanitation is adequate 
Spectrum of clinical illness 
 Clinical presentation ranges from no apparent symptoms to 
severe hypovolemic shock (cholera gravis) 
 Risk factors for cholera gravis include  
• High dose exposure 
• Low gastric acidity: gastrectomy, antacid therapy 
• Blood group O (prevalence in United States ~45%) 
• Other strain and population factors 
Harris JB et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect 
Immun. 2005 Nov;73(11):7422-7.  
http://www.redcrossblood.org/learn-about-blood/blood-facts-and-statistics  
Cholera gravis 
 Profuse watery diarrhea (can be ≥1 L/hour) 
 “Rice-water stools” flecked with mucus and epithelial cells 
 Vomiting 
 Leg cramps 
 Severe dehydration: loss of skin turgor, hypotension, weak 
pulse, altered mental status 
 Rapidly fatal if untreated 
 
Cholera in an American physician, 1971 
 8 AM: acute onset of profuse, brown, watery diarrhea; diffuse 
abdominal cramps; and anorexia 
 9 AM: oral rehydration and antibiotics started 
 11 AM: light-headedness and nausea 
 12 PM: blood pressure 80/60 mm Hg; pulse 116 
 12:20 PM: persistent, severe muscle cramps in both lower legs 
 3 PM: rice-water stool while en route to hospital 
 5 PM (at hospital): 4 kg [8.8 lbs] weight loss since previous week 
 Day 2, 2 PM: discharged, having passed 8,870 ml of stool and 
having received 10.4 liters of intravenous solution 
 4 days later: patient returned to duty 
Abrutyn E et al. Cholera in a vaccinated American. Immunological response to vaccination and disease. Ann Intern 
Med. 1971 Feb;74(2):228-31. 
Diagnosis 
 Diagnosis by culture of rectal swab or stool specimen  
• Underdiagnosis common because special transport media and 
culture media are needed 
 Serologic diagnosis: acute/convalescent vibriocidal titers 
• Increase 2 weeks after exposure 
• Decrease 2 months after illness 
Clinical management 
 Supportive care: oral/intravenous rehydration can reduce 
fatality rate to <1% 
 Antimicrobial therapy in conjunction with hydration 
• Recommended for severely ill patients and all hospitalized 
patients  
• Reduces fluid loss, duration of illness, duration of fecal carriage 
 Zinc supplementation in children reduces duration of illness 
and volume of diarrhea 
Immunity 
 Vibriocidal antibodies are best marker for protection against 
V. cholerae infections 
 LPS-specific memory B cells may play role in mediating long 
term protection  
 Protection against cholera is serogroup-specific (O1 or O139) 
but protects across biotypes (El Tor and Classical) and 
serotypes (Inaba and Ogawa) 
Cholera in industrialized countries is  
mostly travel-associated 
 Very rare in United States and other countries with safe 
water and modern sanitation 
 Few domestically acquired cases in United States; many of 
them associated with Gulf Coast seafood consumption 




Cholera is underreported in the United States 
 Testing for V. cholerae is not 
routine 
 Some cholera illnesses in 
travelers are not severe and 
may resemble other causes 
of traveler’s diarrhea 
Pathogen identified 
Lab tests for pathogen 
Specimen submitted 
Person seeks care 
Person becomes ill 
Selected estimates of laboratory-confirmed cholera 
incidence in returning travelers 
 Interpretation should consider differences in surveillance methods 
*GeoSentinel clinics: clinics belonging to a worldwide surveillance network that tracks infectious diseases in returned travelers, foreign visitors,  
and immigrants 
 
Wittlinger F et al. Risk of Cholera Among Western and Japanese Travelers. J Travel Med. 1995 Sep 1;2(3):154-158. 
Freedman DO et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J  Med. 2006 Jan 12;354(2):119-30.  
Population Incidence per 
100,000 people 
European and North American travelers to South 
America, 1991 (during cholera epidemic) 
0.3 
Japanese travelers to Indonesia, 1991 13 
All travelers returning from developing world seeking 
care at GeoSentinel clinics*, 1996–2004 
5.8 
Selected estimates of laboratory-confirmed cholera incidence 
among persons traveling or living in cholera-affected areas 
 Haiti, December 2010: Cholera outbreak affected 10/14 (71%) French medical 
volunteers and 11/72 (15%) French military police engaged in response efforts 
* 1 of 311 respondents reported receiving a diagnosis of cholera 
**  0 cholera cases diagnosed among 898 travelers seeking care for traveler’s diarrhea 
 
Taylor DN et al. Cholera among Americans living in Peru. Clin Infect Dis. 1996 Jun;22(6):1108-9. 
Schilling KA et al. Diarrheal illness among US residents providing medical services in Haiti during the cholera epidemic, 2010 to 2011. J Travel 
Med. 2014 Jan-Feb;21(1):55-7. 
Murphy H, Pandey P. Pathogens for travelers' diarrhea in Nepal and resistance patterns. Curr Infect Dis Rep. 2012 Jun;14(3):238-45. 
Haus-Cheymol R et al. A cluster of acute diarrhea suspected to be cholera in French travelers in Haiti, December 2010. J Travel Med. 2012 
May-Jun;19(3):189-91.  
Population Incidence per 100,000 
people 
US citizens living in Peru, 1991–1993 44 per month 
US citizens providing medical services in Haiti, 
2010–2011 
321* 
Travelers seeking care during travel to Nepal, 
multiple years between 1986 and 2011 
0** 
Cholera outbreak among passengers of a commercial 
airline flight from South America, 1992 
 Flight from Buenos Aires, Argentina  Lima, Peru  Los 
Angeles, United States 
 Contaminated seafood salad prepared in Lima and served to 
passengers 
 100/194 passengers tested had evidence of V. cholerae O1 
infection 
• 75 had diarrhea (median 2 days after arrival) 
• 10 patients hospitalized 
• 1 patient died (70 years of age) 
• 19 cholera patients were US citizens 
Eberhart-Phillips J et al. An outbreak of cholera from food served on an international aircraft. Epidemiol Infect. 1996 
Feb;116(1):9-13.  
Cholera in the United States, 2001–2011 
 111 cholera cases reported in United States over 11-year 
period 
 Epidemic cholera began in Haiti in October 2010 
 46% of cases over study period reported after Haiti 
epidemic began 
 No secondary cases reported 
 
Loharikar A et al. Cholera in the United States, 2001-2011: a reflection of patterns of global epidemiology and travel. Epidemiol Infect. 2015 
Mar;143(4):695-703.  
Cholera in the United States, 2001–2011 
 20 (18%) domestically acquired; most reported seafood 
consumption 
 90 (81%) associated with international travel 
• Visiting friends and relatives (62%) 
• Medical missions or other relief work (9%) 
• Tourism (7%) 
• Business (7%) 
• Immigration to the United States (5%) 
 74/87 (85%) travel-associated V. cholerae O1 cases had 
isolate with multidrug resistance 
 
 
Laboratory characteristics of isolates from cholera 
cases— United States, 2001–2011 








Laboratory characteristics of isolates from cholera 
cases— United States, 2001–2011 








V. cholerae O1 
n=107 (99%)  
V. cholerae O139 
n=1 (1%) 
Laboratory characteristics of isolates from cholera 
cases— United States, 2001–2011 








V. cholerae O1 
n=107 (99%)  
V. cholerae O139 
n=1 (1%) 
El Tor Inaba 
22 (21%) 
El Tor Ogawa 
85 (79%) 
Number of cholera cases by year, and by source 2001–
2011, United States (n=111) 
Loharikar A et al. Cholera in the United States, 2001-2011: a reflection of patterns of global epidemiology and travel. Epidemiol Infect. 2015 
Mar;143(4):695-703.  
Cholera and Other Vibrio Illness Surveillance—  
United States, 2012–2013 
 30/32 (94%) patients with cholera reported in United States 
had traveled to cholera-endemic area 
• Haiti (18), Dominican Republic (4), Other (8) 
 1 healthcare worker with no travel exposure who cared for a 
cholera patient in the hospital 
 1 reported exposure in a laboratory 
 Age 1–87 years 
http://www.cdc.gov/ncezid/dfwed/pdfs/covis-annual-report-2012-508c.pdf . Accessed October 8, 2015.  
http://www.cdc.gov/ncezid/dfwed/pdfs/covis-annual-report-2013-508c.pdf . Accessed October 8, 2015.  
Summary of cholera features 
 Severe cholera (cholera gravis) can be rapidly fatal if 
untreated 
 Cholera is under-reported 
 Few cases are reported in the United States, although 
incidence increased after outbreak in Haiti began 
 Most cases in United States occur in persons who have 
recently traveled to cholera-affected areas 
 Few cases in healthcare workers and laboratory personnel 
providing medical services to cholera patients 
Current CDC recommendations for US travelers to 
cholera-affected areas 
 Current prevention recommendations center on safe food 
and water precautions and frequent handwashing 
 Chemoprophylaxis not indicated 
 No vaccine recommendation; no cholera vaccine licensed in 
United States 
 WHO prequalified vaccines (Dukoral, Shanchol) are 
mentioned 
 
http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/cholera. Accessed October 8, 2015 
WHO recommendations for travelers to cholera-
endemic areas 
 “The risk for most travelers is very low, even in countries 
where cholera epidemics occur, provided that simple 
precautions are taken. However, humanitarian relief workers 
in disaster areas and refugee camps may be at risk” 
 Consider for travelers at high risk: 
• Killed oral O1 with whole-cell with B-subunit (Dukoral) 
• Killed oral O1 and O139 (Shanchol) 
 
 October 2, 2015: SAGE* Working Group forming to revise 
WHO recommendations on oral cholera vaccines 
* Strategic Advisory Group of Experts (SAGE) on Immunization 
http://www.who.int/ith/vaccines/cholera/en/. Accessed October 8, 2015.  
http://www.who.int/immunization/policy/sage/call_sage_wg_ocv/en/. Accessed October 8, 2015.  
Global cholera vaccines for travelers 
 No vaccine licensed in United States 
 Shanchol (ShanthaBiotechnics, India) 
• Licensed in India 
• 2 oral doses 2–6 weeks apart 
 Dukoral (Crucell, the Netherlands)  
• Licensed in >60 countries, primarily as vaccine for travelers to 
cholera-endemic areas 
• Sweden and Canada: approved for traveler’s diarrhea prevention 
• Short-term protection against enterotoxigenic E. coli 
• 2 oral doses ≥7 days apart; requires buffer solution 
 No country requires vaccination against cholera as condition 
for entry 
 
CVD 103-HgR: single-dose, live attenuated oral cholera 
vaccine under consideration for US travelers 
 Recombinant V. cholerae O1, Classical biotype, serotype 
Inaba; confers protection against multiple biotypes and 
serotypes 
 94% of the enzymatically active A subunit of toxin gene 
deleted 
 Gene for the antigenic, non-toxic B subunit of toxin intact 
 Does not express enzymatically active cholera toxin 
 Contains marker to differentiate the vaccine strain from 
wild-type V. cholerae O1 
 
CVD 103-HgR: single-dose, live attenuated oral cholera 
vaccine under consideration for US travelers 
 Previously licensed as Orochol/Mutacol and used in non-US 
countries including Switzerland, Canada, Australia 
 Manufacture ceased for business reasons in 2004 
 In 2009, PaxVax acquired licensure rights to redevelop CVD 
103-HgR (Vaxchora) for commercial use 
ACIP Cholera Vaccine Work Group 
 Review evidence for use of CVD 103-HgR and evaluate 
according to GRADE framework 
 Inform recommendations for use of CVD 103-HgR in adult 
travelers in anticipation of US licensure 
Anticipated next steps 
 February 2016: Presentation of GRADE evaluation; 
presentation by vaccine manufacturer 
 June 2016: Presentation of working group recommendations 
regarding use in adult travelers 
Thank you 
For more information please contact Centers for Disease Control and Prevention 
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Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348 
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